Peptides Research Guide: Clinical Evidence, Mechanisms & Safety

Introduction

Peptides have become one of the most discussed topics in sports medicine, anti-aging research, and regenerative medicine — and one of the most misunderstood. The word "peptide" refers simply to a chain of two or more amino acids linked by peptide bonds. Proteins are peptides; insulin is a peptide; the signaling molecules that regulate growth, hunger, and tissue repair are peptides. The supplement and clinical research landscape encompasses a wide spectrum ranging from well-characterized collagen peptides with robust RCT data, to experimental growth hormone secretagogues used in endocrinology clinics, to largely unregulated research compounds like BPC-157 that have compelling animal data but very limited human trial evidence.

This article systematically reviews the research on the most commonly discussed peptide categories: collagen peptides, growth hormone secretagogues (GHS), body protection compound (BPC-157), thymosin beta-4 (TB-500), and related compounds. For each, we examine the proposed mechanisms, the quality and strength of the available evidence, the clinical applications where evidence exists, and the safety and regulatory context. Citations are drawn from PubMed-indexed peer-reviewed literature, NIH-supported research, and government databases.

Understanding the hierarchy of evidence is essential when evaluating peptide research. A randomized, double-blind, placebo-controlled trial (RCT) in humans provides the highest quality of causal evidence. Observational studies, case series, and animal studies form a lower tier. Much of the compelling peptide research — particularly for BPC-157 — sits at the animal study level, which makes mechanistic extrapolation to humans speculative. Where human RCT data exists (collagen peptides, sermorelin), the evidence is considerably stronger and supports more confident clinical conclusions.

---

What Are Peptides? Biology and Classification

Peptides are defined by their length: conventionally, chains of 2–50 amino acids are peptides; longer chains are proteins, though the boundary is not fixed. Biologically, peptides function as hormones, neurotransmitters, growth factors, antimicrobial agents, and signaling molecules. The human genome encodes thousands of peptides with regulatory functions.

Endogenous vs. Exogenous Peptides

Endogenous peptides are produced naturally by the body. Examples include:

• Insulin (51 amino acids) — regulates glucose uptake
• Glucagon (29 amino acids) — raises blood glucose
• Growth hormone (191 amino acids, technically a protein) — promotes growth and metabolism
• Ghrelin (28 amino acids) — appetite-stimulating peptide secreted by the stomach
• Thymosin beta-4 — actin-sequestering peptide with roles in wound healing and tissue repair

Exogenous peptides are taken from outside the body — either through food, oral supplements, or injection. Collagen peptides consumed orally are absorbed as short-chain amino acids and dipeptides; they do not function like a drug but rather supply raw material for endogenous collagen synthesis. Injectable peptides like growth hormone secretagogues or BPC-157 operate via receptor-mediated pharmacological mechanisms and carry a fundamentally different risk and evidence profile.

Peptide Stability and Delivery

A key pharmacological challenge with peptides is bioavailability. Most peptides are rapidly degraded by gastrointestinal proteases when taken orally. This is why:

• Collagen peptides are specifically hydrolyzed to be stable and bioavailable when consumed orally
• Growth hormone secretagogues are typically injected subcutaneously to bypass first-pass degradation
• Pharmaceutical peptides like insulin require injection for the same reason

Research into oral peptide delivery — including enteric coatings, nanoparticle encapsulation, and cyclization — is active but has not yet yielded widely available commercial products with proven clinical efficacy matching injectable forms.

---

Collagen Peptides: The Best-Evidenced Category

Collagen is the most abundant protein in the human body, constituting the structural scaffold of skin, bone, cartilage, tendons, and ligaments. It is synthesized from procollagen precursors by fibroblasts and chondrocytes, in a process requiring vitamin C, zinc, copper, and specific amino acids — primarily glycine, proline, and hydroxyproline.

Collagen peptides (also called hydrolyzed collagen or collagen hydrolysate) are derived from animal sources — bovine, marine, or porcine — by enzymatic hydrolysis that breaks the protein into short-chain peptides of 2–9 amino acids. These short fragments are absorbed across the intestinal wall, enter systemic circulation, and accumulate in connective tissue.

Mechanism: How Collagen Peptides Work

The mechanism by which collagen peptides exert biological effects involves two pathways:

1. Substrate supply: Collagen peptides are particularly rich in glycine (~33% by weight), proline, and hydroxyproline — the three amino acids most critical to collagen triple-helix formation. Supplementation increases the availability of these specific building blocks for fibroblast and chondrocyte collagen synthesis.

2. Cell signaling: Specific dipeptides and tripeptides derived from collagen hydrolysis — particularly hydroxyproline-containing fragments — have been shown in vitro to stimulate fibroblast proliferation and increase collagen type I synthesis directly. This suggests collagen peptides act as partial agonists at fibroblast receptors, functioning more like bioactive signaling molecules than passive amino acid sources.

Clinical Evidence: Skin

Proksch et al. (2014, PMID 24401291) conducted a randomized, double-blind, placebo-controlled study in 69 women aged 35–55, examining the effects of 2.5 g/day bioactive collagen peptides for 8 weeks versus placebo on skin elasticity, moisture, and wrinkle depth. The collagen peptide group showed a statistically significant 15% improvement in skin elasticity (p < 0.05), a 20% reduction in eye wrinkle depth on ultrasound measurement, and improved skin moisture retention. These effects persisted at 4-week post-supplementation follow-up, suggesting durable changes in the dermal extracellular matrix rather than transient hydration effects.

Meta-analyses of collagen peptide supplementation for skin aging (multiple RCTs pooled) consistently find moderate but statistically significant improvements in skin hydration, elasticity, and wrinkle depth at doses of 2.5–10 g/day. The effect sizes are comparable to those achieved with topical retinoids but without the irritation profile.

Clinical Evidence: Joints

Clark et al. (2008, PMID 18416885) conducted a 24-week, randomized, double-blind study in 147 athletes at Penn State University examining 10 g/day collagen hydrolysate versus placebo on joint pain at rest, during activity, and after exercise, measured by visual analog scale. The collagen peptide group showed statistically significant improvements in joint pain at rest (p < 0.05), during ambulation (p < 0.05), and with activity (p < 0.05), with the greatest absolute differences seen in knee pain with activity. This was an athlete population, suggesting potential utility for both clinical and performance-oriented joint protection.

Shaw et al. (2017, PMID 27852613) demonstrated in an RCT that 15 g/day collagen peptides combined with vitamin C taken one hour before exercise led to significantly higher collagen synthesis markers (blood aminoterminal propeptide of collagen type I — N-terminal telopeptide) compared to placebo, along with improvements in collagen fibril formation in engineered ligament models ex vivo. This provides mechanistic support for pre-exercise collagen loading as a joint protection strategy.

Clinical Evidence: Muscle and Body Composition

Zdzieblik et al. (2015, PMID 26353786) enrolled 53 elderly sarcopenic men in a 12-week randomized, double-blind, placebo-controlled trial comparing 15 g/day collagen peptides plus resistance training against resistance training alone. The collagen peptide group showed significantly greater gains in fat-free mass (+4.2 kg vs. +2.9 kg, p < 0.05) and greater loss of fat mass, as well as increased muscle strength (leg press, p < 0.05). This result suggests collagen peptides may synergize with resistance training for muscle hypertrophy and fat loss, particularly in older populations with compromised collagen synthetic capacity.

Clinical Evidence: Bone

König et al. (2018, PMID 29337906) randomized 102 postmenopausal women with primary osteopenia to 5 g/day specific collagen peptides or placebo for 12 months. Bone mineral density at the spine increased significantly in the collagen group (+3.16% vs. −0.03% for placebo, p < 0.05), and bone marker profiles showed increased bone formation (procollagen type I N-terminal propeptide) and decreased bone resorption (C-terminal telopeptide of collagen type I). This is one of the stronger intervention studies in bone health for any natural compound.

Summary Table: Collagen Peptide Evidence

---

Growth Hormone Secretagogues

Growth hormone secretagogues (GHS) are a class of peptides and small molecules that stimulate the pituitary gland to release endogenous growth hormone (GH). Unlike direct GH administration, GHS preserve the pulsatile, physiological pattern of GH release and do not shut down the hypothalamic-pituitary-somatotropic axis. This distinction has important implications for safety and clinical appropriateness.

The GH Axis: A Brief Primer

Growth hormone is released from the anterior pituitary in pulsatile bursts — primarily during deep slow-wave sleep — in response to two upstream signals:

• Growth hormone-releasing hormone (GHRH) from the hypothalamus — stimulates GH release
• Somatostatin from the hypothalamus — inhibits GH release
• Ghrelin (and its receptor, GHSR-1a) — potently stimulates GH release, primarily from the stomach but also expressed centrally

GHS work by mimicking either GHRH (GHRH analogs: sermorelin, tesamorelin, CJC-1295) or ghrelin (GHRPs: ipamorelin, GHRP-2, GHRP-6, hexarelin). Some protocols combine both a GHRH analog and a GHRP to achieve synergistic GH release.

Sermorelin

Sermorelin (GHRH 1–29 NH₂) is the synthetic form of the first 29 amino acids of endogenous GHRH. It was FDA-approved in 1990 for the diagnosis of GH deficiency and later for treatment of idiopathic GH deficiency in children. It is sometimes used off-label by clinicians for adult GH deficiency and age-related GH decline.

Walker (2006, PMID 17255569) reviewed the pharmacology and clinical use of sermorelin, noting that because it stimulates the pituitary through the natural GHRH receptor, GH release remains subject to the normal feedback loops from IGF-1 and somatostatin — a built-in safety mechanism absent with direct GH injection. Clinical effects include improvements in body composition, sleep quality, energy, and lean mass in GH-deficient adults, with fewer adverse effects than exogenous GH. The main limitation is that pituitary responsiveness must be preserved for sermorelin to be effective.

Ipamorelin

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the ghrelin receptor (GHSR-1a) to stimulate GH release without significantly increasing cortisol, prolactin, or ACTH — a key selectivity advantage over earlier GHRPs like GHRP-2 or GHRP-6, which produce more broad hormonal stimulation.

Raun et al. (1998, PMID 9849822) characterized ipamorelin as the first selective GH secretagogue, demonstrating in animal studies that it produced a robust GH pulse comparable to GHRP-6 while having minimal effect on cortisol and prolactin — a profile suggesting greater clinical tolerability. Garcia, Merriam, and Kargi (2013, PMID 24672499) reviewed the use of GHS in aging, noting that the blunted GH secretion in older adults (somatopause) correlates with sarcopenia, increased adiposity, and reduced quality of life, and that GHS may partially restore pulsatile GH secretion without the risks associated with supraphysiological GH replacement.

CJC-1295 with DAC

CJC-1295 is a synthetic GHRH analog modified with a Drug Affinity Complex (DAC) that enables binding to plasma albumin, extending its half-life from minutes (for native GHRH) to approximately 8 days. This dramatically changes its pharmacokinetic profile — from producing physiological pulses to maintaining elevated GH and IGF-1 levels continuously.

This longer half-life is pharmacologically consequential: rather than simulating the natural pulsatile GH release that occurs during sleep, CJC-1295 with DAC produces tonic GH elevation. Whether this is preferable to the pulsatile profile (which is preferred by most endocrinologists for safety) is debated. CJC-1295 without DAC (also called Mod GRF 1-29) has a shorter half-life and produces more physiological GH pulses. The distinction matters clinically: chronic tonic GH stimulation may carry greater long-term risks (including potential IGF-1-mediated cell proliferation) compared to pulsatile administration.

Growth Hormone Secretagogue Receptor and Metabolic Effects

Zhang et al. (2010, PMID 21048778) reviewed the role of the GHSR (ghrelin receptor) in energy and glucose homeostasis, noting that GHSR activation modulates insulin secretion, adipogenesis, and glucose uptake. This dual role — promoting GH release while also affecting metabolic set points — is why GHS research intersects with both endocrinology and metabolic medicine. The authors identified the GHSR as a therapeutic target for obesity and metabolic dysfunction, beyond its traditional role in GH axis management.

Arvat et al. (1997, PMID 9351474) examined the acute hormonal effects of GHRP-6 in humans, finding that while it stimulates GH release, it also transiently decreases insulin levels and modestly increases glucagon — metabolic effects that warrant monitoring in diabetic or pre-diabetic individuals using GHS.

---

BPC-157: Body Protection Compound

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in the human gastric juice protein BPC. It is designated a stable gastric pentadecapeptide because unlike most peptides, it resists gastric acid degradation. It is not FDA-approved for any human indication; all published human-relevant clinical trials have been conducted with earlier, less stable analogs for inflammatory bowel disease.

Mechanisms

BPC-157 has been studied extensively in rodent models across a range of injury paradigms. Proposed mechanisms include:

• Nitric oxide (NO) pathway modulation: BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) and NO production in endothelial cells, which promotes vasodilation, angiogenesis, and tissue perfusion — critical to wound healing.
• Growth factor upregulation: Animal studies show BPC-157 increases local expression of EGR-1 (early growth response protein 1), a transcription factor that upregulates VEGF, collagen, and fibronectin synthesis. This mechanism could explain accelerated wound healing and tendon repair observed in rodent models.
• Gut-brain axis effects: BPC-157 interacts with dopaminergic and serotonergic systems in animal models, producing anxiolytic-like behavior in the elevated plus maze and reducing depressive-like behavior in the forced swim test.
• Cytoprotection: The compound was originally studied for gastrointestinal cytoprotection, where it shows remarkable protective effects against NSAID-induced gastric ulceration, alcohol-induced gut injury, and inflammatory bowel conditions in rats.

The Animal Evidence

Sikiric et al. (2013, PMID 23930283) summarized the trajectory of BPC-157 research, noting that the compound has been studied in trials for inflammatory bowel disease under designations PL-10, PLD-116, and PL 14736, but that published human trial data remains limited. The animal literature — primarily in rat models of colitis, tendon injury, bone fracture, muscle tear, and spinal cord injury — consistently shows accelerated healing, reduced inflammation, and improved functional recovery across injury types. The compound appears remarkably non-toxic in animal studies, with no lethal dose identified in rodents at doses many times the proposed therapeutic range.

Sikiric et al. (2016, PMID 26874808) specifically reviewed BPC-157's central nervous system effects, reporting neuroprotective properties in models of traumatic brain injury, stroke, Parkinson's disease-like lesions, and antipsychotic-induced extrapyramidal effects — effects again consistently shown in rodents. In a particularly interesting observation, BPC-157 counteracted the QTc-prolonging effects of multiple antipsychotic drugs in rats (PMID 28349572), suggesting possible cardioprotective properties.

The Evidence Gap: Animal to Human

The critical issue with BPC-157 is the enormous gap between animal study evidence and human clinical data. Animal models of injury and healing do not reliably predict human outcomes — the history of medicine contains dozens of compounds that showed dramatic efficacy in rodent healing models but failed or showed unexpected harms in human trials. BPC-157 has:

• No completed Phase II or Phase III human RCTs published in peer-reviewed journals for any indication
• No FDA approval or IND (Investigational New Drug) designation for human use
• No established human pharmacokinetic data (dosing, half-life, metabolism, clearance)
• Regulatory status as a research chemical only — not for human use

This does not mean BPC-157 is ineffective in humans — it means we do not have the evidence to know. The robust and consistent animal data justifies further human research, which appears to be progressing. However, individuals using BPC-157 obtained as a research chemical and self-administering without medical supervision are doing so with essentially no evidence-based human dosing guidance and meaningful contamination and infection risk from unregulated injectable products.

---

Thymosin Beta-4 (TB-500)

Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide originally isolated from thymic tissue and subsequently found to be ubiquitously expressed throughout the body. It is one of the most abundant intracellular peptides in mammalian tissues, where it functions primarily as an actin-sequestering molecule — binding to G-actin monomers to regulate the dynamic equilibrium of the actin cytoskeleton. This function connects it to cell motility, wound healing, angiogenesis, and tissue repair.

TB-500 is a synthetic fragment of Tβ4, specifically the actin-binding domain sequence LKKTETQ. It is marketed as a research chemical (not for human use) and has attracted significant interest in athletic and anti-aging communities for its purported wound-healing, anti-inflammatory, and muscle repair properties.

Cardiac Repair Research

The most rigorous research on Tβ4 has focused on cardiac regeneration following myocardial infarction. Bock-Marquette et al. (2004, PMID 15283668) demonstrated that thymosin beta-4 activates integrin-linked kinase (ILK) and promotes cardiac cell migration and survival in mouse models of myocardial infarction. Mice treated with Tβ4 showed significantly improved cardiac function and reduced infarct size. This study established a mechanistic basis for Tβ4's cardioprotective effects — the ILK/Akt signaling pathway governing cell survival and migration.

Smart and Riley (2008, PMID 18434030) reviewed the role of thymosin beta-4 in cardiac repair, highlighting its capacity to activate the epicardium — a quiescent cell layer covering the heart — causing epicardial cells to undergo epithelial-to-mesenchymal transition and migrate into the myocardium where they contribute to new vessel formation and potentially cardiomyocyte regeneration. This was a significant finding because epicardial activation was thought to be a developmentally restricted process. Human trials for cardiac repair using Tβ4 are ongoing but have not yet yielded published efficacy data from Phase II/III RCTs.

Wound Healing and Tissue Repair

Beyond cardiac applications, animal studies document Tβ4's ability to accelerate dermal wound healing, reduce inflammation in corneal injury models, promote nerve regeneration after peripheral nerve crush injury, and reduce fibrotic scarring in multiple organ models. The common thread is cytoskeletal reorganization: by modulating actin dynamics, Tβ4 promotes cell migration into wound sites, facilitates matrix deposition, and reduces the inflammatory-to-fibrotic transition that causes scarring.

Evidence Limitations

Like BPC-157, the human evidence base for TB-500 is minimal. The athletic community has generated anecdotal reports of accelerated tendon and muscle injury recovery, but these are not controlled observations. No published RCTs in human athletes exist. The natural endogenous Tβ4 peptide has an excellent safety record in animal toxicology, and early-phase human trials for cardiac indications have not flagged serious safety signals — but the compound is uncharacterized at the doses and frequency used for musculoskeletal applications outside formal trial settings.

---

Peptide Safety, Regulation, and Practical Considerations

Regulatory Framework

The regulatory status of peptides varies enormously by compound and jurisdiction:

FDA-approved peptides for human use (selected examples):

• Sermorelin — previously approved for GH deficiency
• Tesamorelin (Egrifta) — approved for HIV-associated lipodystrophy
• Bremelanotide (Vyleesi) — melanocortin receptor agonist approved for HSDD
• Semaglutide (Ozempic/Wegovy) — GLP-1 receptor agonist approved for type 2 diabetes and obesity

Research chemicals (not for human use):

• BPC-157, TB-500 (thymosin beta-4 fragment), ipamorelin (when obtained without prescription), CJC-1295 without DAC

Compounded peptides: The FDA's 2023 regulatory actions placed several peptides on a list of substances that cannot be compounded for human use, including BPC-157, TB-500, and several GHRPs, citing insufficient evidence of safety and efficacy outside approved indications.

Safety Considerations by Category

Collagen peptides have an excellent safety record. No serious adverse events have been reported in clinical trials at doses of 2.5–15 g/day. Gastrointestinal side effects (bloating, heaviness) are occasionally reported but mild. Individuals with severe fish or shellfish allergies should choose bovine rather than marine-sourced products. There are no significant drug interactions.

Growth hormone secretagogues (medically supervised use): Side effects include transient water retention, tingling at injection sites, and mild hypoglycemia. Elevated IGF-1 carries theoretical cancer-risk implications in individuals with pre-existing neoplastic conditions; this is why oncologists screen for GH therapy prior to initiation. In properly screened patients, short-term GHS use appears well-tolerated. Long-term safety data beyond 6–12 months is limited.

BPC-157 and TB-500 (self-administered, unregulated): The primary concerns are:

• Contamination risk: Unregulated research chemical products are not manufactured under pharmaceutical GMP standards. Bacterial contamination, incorrect dosing (labeled vs. actual content), and improper lyophilization have been documented in independent testing of grey-market peptide vials.
• Infection risk: Subcutaneous or intramuscular injection with non-sterile technique is a known vector for soft-tissue infections, including MRSA.
• Unknown long-term effects: No human chronic toxicology data exists for these compounds at doses used recreationally.

Distinguishing Evidence Tiers

---

Collagen Peptide Dosing and Practical Protocol

For the evidence-supported use of collagen peptides — skin, joints, muscle, and bone — the following practical guidance derives from the clinical trial literature:

Skin and Dermal Health

A dose of 2.5–5 g/day of hydrolyzed collagen peptides is supported by multiple skin RCTs. Effects develop over 8–12 weeks of consistent use. Adding vitamin C (500–1000 mg) at the same time as collagen peptides enhances hydroxylation of proline and lysine, which is rate-limiting for collagen triple-helix formation. Evening administration alongside a protein-rich meal appears reasonable for amino acid co-delivery.

Joint Health and Tendon/Ligament Support

10 g/day is the dose used in the Clark et al. athlete trial showing joint pain reduction. For tendon and ligament applications, Shaw et al. suggest taking 15 g collagen + 50 mg vitamin C approximately 60 minutes before exercise to maximize collagen synthesis during the post-exercise repair window — when fibroblasts are most active. This pre-exercise loading strategy is supported by the ex vivo ligament synthesis data in their study.

Body Composition (Sarcopenia)

The Zdzieblik et al. protocol used 15 g/day combined with progressive resistance training 3 times/week for 12 weeks. Collagen peptides are not a replacement for complete protein sources (they lack adequate tryptophan and are low in branched-chain amino acids) but appear to synergize with resistance training for connective tissue adaptation in older adults.

Bone Health

König et al. used 5 g/day for 12 months in postmenopausal women with osteopenia. The bone effect appears to require sustained supplementation, consistent with the slow turnover rate of bone matrix. This dose is appropriate to combine with vitamin D and calcium if those are also deficient.

---

What Peptide Research Cannot Yet Answer

The field of peptide research is advancing rapidly, and several important questions remain open:

1. Oral vs. injectable bioavailability of research peptides. Some researchers and clinicians argue that BPC-157, in particular, may be effective orally given its stability in gastric juice — this is consistent with its origin as a gastric protein-derived fragment. If this holds in human pharmacokinetic studies, the risk profile of BPC-157 would be fundamentally different from injectable use. No published human PK data confirms this.

2. Long-term IGF-1 safety. Growth hormone secretagogues elevate IGF-1, which is mitogenic (promotes cell growth). The long-term implications for cancer risk in healthy individuals are not resolved by existing data. Short-term and medium-term (1–2 year) data from GH-deficient patients on GHS does not show elevated cancer incidence, but these are medically supervised patients with baseline screening that recreational users lack.

3. Peptide stacking and interactions. Many practitioners combine GHRPs with GHRH analogs (e.g., ipamorelin + CJC-1295), but synergistic effect data in humans is sparse, and the additive hormonal burden of such combinations on feedback loops has not been characterized long-term.

4. BPC-157 in human clinical trials. The most pressing unmet need in peptide research is the translation of BPC-157 animal data into rigorous human RCTs, particularly for musculoskeletal injury, IBD, and neurological applications. Given the consistent animal evidence, this research gap is a priority for academic and pharmaceutical investigation.

---

Conclusion

Peptides represent one of the most heterogeneous and rapidly evolving areas in sports medicine, anti-aging science, and regenerative biology. The evidence spectrum is wide:

At one end, collagen peptides stand out as one of the most rigorously studied natural compounds in human clinical trials, with consistent evidence across skin elasticity, joint pain, bone mineral density, and muscle composition outcomes at accessible oral doses. Their safety is excellent and their mechanism — substrate supply plus cell signaling — is well-characterized. For any individual interested in connective tissue health, collagen peptide supplementation at 5–15 g/day is supported by multiple high-quality RCTs.

In the middle, growth hormone secretagogues like sermorelin and ipamorelin have legitimate clinical applications in medically diagnosed GH deficiency and are managed appropriately with physician oversight, regular IGF-1 monitoring, and screening for contraindications. Their off-label use requires careful patient selection and is not appropriate for self-administration without medical supervision.

At the other end, BPC-157 and thymosin beta-4 have fascinating and consistent animal data that justifies research interest and enthusiasm — but these compounds have not completed human clinical trials, lack established human pharmacokinetics, and are currently sold only as unregulated research chemicals carrying real infection and contamination risks when self-administered by injection. The intellectual excitement of the animal data should not be confused with clinical evidence of human efficacy and safety.

For anyone navigating the peptide landscape, the key intellectual discipline is tracking evidence tiers: animal data is hypothesis-generating, not confirmatory. Human RCT data — ideally replicated, blinded, and in relevant populations — is what should guide decisions about personal use. The peptide field is producing that data at an accelerating pace. Collagen peptides already have it; GHRPs are accumulating it; BPC-157 desperately needs it.

---

References

Related Articles

• Creatine for Brain Health
• How to Choose a Quality Supplement
• Natural Compounds Research Clusters